These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 38603464)

  • 21. Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritis.
    Li X; Andersen KM; Chang HY; Curtis JR; Alexander GC
    Ann Rheum Dis; 2020 Feb; 79(2):285-291. PubMed ID: 31672774
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A short history of biological therapy for psoriatic arthritis.
    Mease P
    Clin Exp Rheumatol; 2015; 33(5 Suppl 93):S104-8. PubMed ID: 26472182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The concept of psoriatic disease: can cutaneous psoriasis any longer be separated by the systemic comorbidities?
    Lotti T; Hercogova J; Prignano F
    Dermatol Ther; 2010; 23(2):119-22. PubMed ID: 20415818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost per responder of biologic drugs used in the treatment of moderate-to-severe plaque psoriasis in France and Germany.
    Nyholm N; Schnack H; Danø A; Skowron F
    Curr Med Res Opin; 2023 Jun; 39(6):833-842. PubMed ID: 37203343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The therapeutic potential of TNF-alpha antagonists for skin psoriasis comorbidities.
    Piérard GE; Piérard-Franchimont C; Szepetiuk G; Paquet P; Quatresooz P
    Expert Opin Biol Ther; 2010 Aug; 10(8):1197-208. PubMed ID: 20560729
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In the Real World: Infections Associated with Biologic and Small Molecule Therapies in Psoriatic Arthritis and Psoriasis.
    Siegel SAR; Winthrop KL
    Curr Rheumatol Rep; 2019 Jun; 21(7):36. PubMed ID: 31172303
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Biologics. New drugs, new adverse reactions].
    Prinz JC
    Hautarzt; 2010 Aug; 61(8):668-75. PubMed ID: 20585746
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TNF-α in a molecularly targeted therapy of psoriasis and psoriatic arthritis.
    Wcisło-Dziadecka D; Zbiciak-Nylec M; Brzezińska-Wcisło L; Mazurek U
    Postgrad Med J; 2016 Mar; 92(1085):172-8. PubMed ID: 26719452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Can early treatment with biologicals modify the natural history of comorbidities?
    Vena GA; Vestita M; Cassano N
    Dermatol Ther; 2010; 23(2):181-93. PubMed ID: 20415826
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Integrated approach to comorbidity in patients with psoriasis.Working Group on Psoriasis-associated Comorbidities].
    Daudén E; Castañeda S; Suárez C; García-Campayo J; Blasco AJ; Aguilar MD; Ferrándiz C; Puig L; Sánchez-Carazo JL;
    Actas Dermosifiliogr; 2012 Jan; 103 Suppl 1():1-64. PubMed ID: 22364603
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.
    D'Adamio S; Silvaggio D; Lombardo P; Bianchi L; Talamonti M; Galluzzo M
    Expert Opin Drug Saf; 2019 Nov; 18(11):1031-1041. PubMed ID: 31479282
    [No Abstract]   [Full Text] [Related]  

  • 32. Adalimumab for the treatment of severe psoriasis and psoriatic arthritis.
    Papoutsaki M; Costanzo A; Chimenti MS; Chimenti S
    Expert Opin Biol Ther; 2008 Mar; 8(3):363-70. PubMed ID: 18294106
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Guselkumab for the Treatment of Psoriasis.
    Machado Á; Torres T
    BioDrugs; 2018 Apr; 32(2):119-128. PubMed ID: 29470778
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis.
    Lee MP; Desai RJ; Jin Y; Brill G; Ogdie A; Kim SC
    JAMA Dermatol; 2019 Jun; 155(6):700-707. PubMed ID: 30916734
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review.
    Armstrong AW; Brezinski EA; Follansbee MR; Armstrong EJ
    Curr Pharm Des; 2014; 20(4):500-12. PubMed ID: 23565631
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Therapeutic drug monitoring with biologic agents in immune mediated inflammatory diseases.
    Papamichael K; Vogelzang EH; Lambert J; Wolbink G; Cheifetz AS
    Expert Rev Clin Immunol; 2019 Aug; 15(8):837-848. PubMed ID: 31180729
    [No Abstract]   [Full Text] [Related]  

  • 37. Infectious, oncologic, and autoimmune comorbidities of psoriasis and psoriatic arthritis: a report from the GRAPPA 2012 annual meeting.
    Armstrong AW; Coates LC; Espinoza LR; Ogdie AR; Rich P; Soriano ER
    J Rheumatol; 2013 Aug; 40(8):1438-41. PubMed ID: 23908541
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current status and new developments in the treatment of psoriasis and psoriatic arthritis with biological agents.
    Weger W
    Br J Pharmacol; 2010 Jun; 160(4):810-20. PubMed ID: 20590580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Actual treatments of psoriasis : from etanercept to anti-IL17 and anti-IL23 antagonists].
    Libon F; Lebas E; El Hayderi L; De Schaetzen V; Dezfoulian B; Nikkels AF
    Rev Med Liege; 2020 May; 75(5-6):376-381. PubMed ID: 32496683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Could anti IL12/23 therapy replace anti-TNF biologics?
    Ionescu MA; Lipozencić J
    Acta Dermatovenerol Croat; 2009; 17(3):166-9. PubMed ID: 19818214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.